 BioSpecifics Technologies Corp. NASDAQ: BSTC, a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX in North America, today announced its financial results for the second quarter ended June 30, 2020. 